乳がんモノクローナル抗体の世界市場レポート 2025年

乳がんモノクローナル抗体市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.3％で278億米ドルに成長します。予測期間の成長は、新たなターゲット、バイオシミラー、併用療法、世界の罹患率と高齢化、個別化医療に起因すると考えられます。予測期間における主な動向には、乳がんの早期発見、免疫療法の統合、リキッドバイオプシー、コンパニオン診断、アジュバント療法およびネオアジュバント療法、長期生存支援などの進歩が含まれます。

乳がんの罹患率は世界的に拡大しており、乳がんモノクローナル抗体市場の成長を後押しする構えです。2023年1月現在、米国がん協会の統計によると、乳がん罹患数は顕著に増加しており、2021年の284,200例から2023年には300,590例に増加し、5.76%の成長を示しています。このような世界の乳がん罹患率の急増は、乳がん治療用に特別に設計されたモノクローナル抗体の需要を促進する重要な原動力になると予測されています。

乳がんモノクローナル抗体市場の成長が予測される背景には、乳がんへの対処を目的とした政府の取り組みや資金援助があります。政府の取り組みには、乳がん関連の問題に取り組むために政府機関が指示する戦略、政策、資金が含まれます。注目すべきは、2023年2月に世界保健機関（WHO）が世界乳がんイニシアチブ枠組みを導入したことです。この包括的な枠組みは、早期発見、適時診断、包括的な乳がん管理のための健康増進を提唱することにより、2040年までに250万人の命を救うことを目的としています。このような政府の介入や財政支援は、乳がんモノクローナル抗体市場を牽引する極めて重要な役割を果たすと期待されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界乳がんモノクローナル抗体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の乳がんモノクローナル抗体市場：成長率分析
• 世界の乳がんモノクローナル抗体市場の実績：規模と成長, 2019-2024
• 世界の乳がんモノクローナル抗体市場の予測：規模と成長, 2024-2029, 2034F
• 世界乳がんモノクローナル抗体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の乳がんモノクローナル抗体市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 裸のマブス
• 結合モノクローナル抗体
• 世界の乳がんモノクローナル抗体市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 手術と放射線治療
• 標的療法
• 生物学的療法
• ホルモン療法
• 世界の乳がんモノクローナル抗体市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 小売薬局
• 世界の乳がんモノクローナル抗体市場、ネイキッドMABのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トラスツズマブ（ハーセプチン）
• リツキシマブ
• セツキシマブ
• その他の裸のMAB
• 世界の乳がんモノクローナル抗体市場、結合型MABの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アドトラスツズマブエムタンシン（Kadcyla）
• ブレンツキシマブベドチン
• その他の結合MAB

第7章 地域別・国別分析

• 世界の乳がんモノクローナル抗体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の乳がんモノクローナル抗体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 乳がんモノクローナル抗体市場：競合情勢
• 乳がんモノクローナル抗体市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Daiichi Sankyo Company Ltd.
• Biocad
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Array BioPharma Inc.
• Celldex Therapeutics Inc.
• Celltrion Inc.
• F. Hoffmann-La Roche AG
• Immunomedics Inc.
• MacroGenics Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Puma Biotechnology Inc.
• Seattle Genetics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 乳がんモノクローナル抗体市場2029：新たな機会を提供する国
• 乳がんモノクローナル抗体市場2029：新たな機会を提供するセグメント
• 乳がんモノクローナル抗体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Breast cancer monoclonal antibodies (mAbs) represent a treatment approach employing antibodies in both early-stage and advanced breast cancer scenarios. These antibodies operate by recognizing and binding to specific proteins present on cancer cells. Each mAb targets a distinct protein, necessitating the creation of diverse mAbs to address different cancer types. Their function involves various methods to eliminate cancer cells, depending on the targeted protein.

Two primary types of breast cancer monoclonal antibodies exist: naked mAbs and conjugated mAbs. Naked mAbs refer to antibodies devoid of drugs or radioactive substances, self-contained in their structure. This category constitutes the most common type of mAb used in combating cancer. The treatments involving breast cancer monoclonal antibodies encompass a spectrum including chemotherapy, surgery, radiation therapy, targeted therapy, biologic therapy, and hormone therapy. These treatments find utilization across various healthcare sectors, including hospitals and retail pharmacies, offering diverse therapeutic options for individuals combating breast cancer.

The breast cancer monoclonal antibodies (mAbs) market research report is one of a series of new reports from The Business Research Company that provides breast cancer monoclonal antibodies (mAbs) market statistics, including breast cancer monoclonal antibodies (mAbs) industry global market size, regional shares, competitors with a breast cancer monoclonal antibodies (mAbs) market share, detailed breast cancer monoclonal antibodies (mAbs) market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer monoclonal antibodies (mAbs) industry. This breast cancer monoclonal antibodies (mAbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The breast cancer monoclonal antibodies market size has grown strongly in recent years. It will grow from $18.97 billion in 2024 to $20.18 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the rising prevalence of breast cancer, increasing awareness of breast cancer monoclonal antibodies, growing clinical efficacy, and patient demand.

The breast cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $27.8 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to emerging targets, biosimilars, combination therapies, global incidence and aging population, and personalized medicine. Major trends in the forecast period include advances in early breast cancer detection, immunotherapy integration, liquid biopsies, companion diagnostics, adjuvant and neoadjuvant therapies, and long-term survivorship support.

The expanding incidence of breast cancer globally is poised to fuel the growth of the breast cancer monoclonal antibody market. As of January 2023, statistics from the American Cancer Society revealed a notable increase in breast cancer cases, rising from 284,200 cases in 2021 to 300,590 in 2023, signifying a 5.76% growth. This upsurge in breast cancer prevalence globally is projected to serve as a significant driver propelling the demand for monoclonal antibodies specifically designed for breast cancer treatment.

Anticipated growth in the breast cancer monoclonal antibodies market is attributed to government initiatives and funding aimed at addressing breast cancer. Government initiatives encompass strategies, policies, and funding directed by governmental bodies to tackle breast cancer-related issues. Notably, in February 2023, the World Health Organization introduced the Global Breast Cancer Initiative Framework. This comprehensive framework aims to save 2.5 million lives by 2040 by advocating health promotion for early detection, timely diagnosis, and comprehensive breast cancer management. Such governmental interventions and financial support are expected to be pivotal in driving the market for breast cancer monoclonal antibodies.

Companies operating in the breast cancer monoclonal antibodies sector are strategically investing in targeted and combination therapies, proving to be more efficacious and less toxic than traditional treatment methods. Targeted cancer therapies involve drugs that selectively interfere with molecules specifically involved in cancer cell progression. This approach seeks to eliminate cancer cells while sparing normal cells, potentially offering more effectiveness compared to conventional chemotherapy and radiotherapy. Additionally, combination therapy, involving the use of multiple drugs for a single disease, has shown promising outcomes. For instance, in May 2022, F. Hoffmann-La Roche AG launched PHESGO, an innovative breast cancer treatment combining two monoclonal antibodies, Perjeta and Herceptin, along with hyaluronidase. Administered via subcutaneous injection in tandem with intravenous chemotherapy, PHESGO caters to early and metastatic breast cancer management, pioneering a fixed-dose formulation in oncology. This strategic investment in novel therapies indicates the direction of the breast cancer monoclonal antibodies market.

In December 2023, Pfizer Inc., a pharmaceutical and biotechnology company based in the United States, acquired Seagen Inc. for $42 billion. This acquisition is intended to bolster Pfizer's position in the oncology market by expanding its portfolio of innovative cancer therapies, with a particular focus on developing targeted treatments for various types of cancer, including breast cancer. Seagen Inc. is also a U.S.-based biotechnology company that specializes in creating innovative therapies for cancer treatment, particularly utilizing monoclonal antibodies and antibody-drug conjugates.

Major companies operating in the breast cancer monoclonal antibodies market include Amgen Inc., Mylan N.V., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., Daiichi Sankyo Company Ltd., Biocad, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celldex Therapeutics Inc., Celltrion Inc., F. Hoffmann-La Roche AG, Immunomedics Inc., MacroGenics Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Puma Biotechnology Inc., Seattle Genetics Inc., AstraZeneca plc, Eddingpharm, Eisai Co. Ltd., ImmunoGen Inc., Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Mersana Therapeutics Inc., Immunocore Limited, Immunovative Therapies Ltd.

North America was the largest region in the breast cancer monoclonal antibodies market in 2024. The regions covered in the breast cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the breast cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The breast cancer monoclonal antibodies (mAbs) market consists of sales of trastuzumab, pertuzumab, bevacizumab, and rituximab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Monoclonal Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Naked Mabs; Conjugated Mabs
• 2) By Treatment: Chemotherapy; Surgery & Radiation Therapy; Targeted Therapy; Biologic Therapy; Hormone Therapy
• 3) By End-User: Hospitals; Retail Pharmacies
• Subsegments:
• 1) By Naked MABs: Trastuzumab (Herceptin); Rituximab; Cetuximab; Other Naked MABs
• 2) By Conjugated MABs: Ado-trastuzumab emtansine (Kadcyla); Brentuximab vedotin; Other Conjugated MABs
• Companies Mentioned: Amgen Inc.; Mylan N.V.; Merck & Co. Inc.; Novartis AG; GlaxoSmithKline plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Monoclonal Antibodies Market Characteristics

3. Breast Cancer Monoclonal Antibodies Market Trends And Strategies

4. Breast Cancer Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Breast Cancer Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Breast Cancer Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Breast Cancer Monoclonal Antibodies Market Growth Rate Analysis
• 5.4. Global Breast Cancer Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Breast Cancer Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Breast Cancer Monoclonal Antibodies Total Addressable Market (TAM)

6. Breast Cancer Monoclonal Antibodies Market Segmentation

• 6.1. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Naked Mabs
• Conjugated Mabs
• 6.2. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Surgery & Radiation Therapy
• Targeted Therapy
• Biologic Therapy
• Hormone Therapy
• 6.3. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Retail Pharmacies
• 6.4. Global Breast Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Naked MABs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trastuzumab (Herceptin)
• Rituximab
• Cetuximab
• Other Naked MABs
• 6.5. Global Breast Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Conjugated MABs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ado-trastuzumab emtansine (Kadcyla)
• Brentuximab vedotin
• Other Conjugated MABs

7. Breast Cancer Monoclonal Antibodies Market Regional And Country Analysis

• 7.1. Global Breast Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Breast Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Monoclonal Antibodies Market

• 8.1. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Monoclonal Antibodies Market

• 9.1. China Breast Cancer Monoclonal Antibodies Market Overview
• 9.2. China Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Monoclonal Antibodies Market

• 10.1. India Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Monoclonal Antibodies Market

• 11.1. Japan Breast Cancer Monoclonal Antibodies Market Overview
• 11.2. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Monoclonal Antibodies Market

• 12.1. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Monoclonal Antibodies Market

• 13.1. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Monoclonal Antibodies Market

• 14.1. South Korea Breast Cancer Monoclonal Antibodies Market Overview
• 14.2. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Monoclonal Antibodies Market

• 15.1. Western Europe Breast Cancer Monoclonal Antibodies Market Overview
• 15.2. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Monoclonal Antibodies Market

• 16.1. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Monoclonal Antibodies Market

• 17.1. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Monoclonal Antibodies Market

• 18.1. France Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Monoclonal Antibodies Market

• 19.1. Italy Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Monoclonal Antibodies Market

• 20.1. Spain Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Monoclonal Antibodies Market

• 21.1. Eastern Europe Breast Cancer Monoclonal Antibodies Market Overview
• 21.2. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Monoclonal Antibodies Market

• 22.1. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Monoclonal Antibodies Market

• 23.1. North America Breast Cancer Monoclonal Antibodies Market Overview
• 23.2. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Monoclonal Antibodies Market

• 24.1. USA Breast Cancer Monoclonal Antibodies Market Overview
• 24.2. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Monoclonal Antibodies Market

• 25.1. Canada Breast Cancer Monoclonal Antibodies Market Overview
• 25.2. Canada Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Monoclonal Antibodies Market

• 26.1. South America Breast Cancer Monoclonal Antibodies Market Overview
• 26.2. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Monoclonal Antibodies Market

• 27.1. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Monoclonal Antibodies Market

• 28.1. Middle East Breast Cancer Monoclonal Antibodies Market Overview
• 28.2. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Monoclonal Antibodies Market

• 29.1. Africa Breast Cancer Monoclonal Antibodies Market Overview
• 29.2. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

• 30.1. Breast Cancer Monoclonal Antibodies Market Competitive Landscape
• 30.2. Breast Cancer Monoclonal Antibodies Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Monoclonal Antibodies Market Other Major And Innovative Companies

• 31.1. Daiichi Sankyo Company Ltd.
• 31.2. Biocad
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Bristol-Myers Squibb Company
• 31.5. Array BioPharma Inc.
• 31.6. Celldex Therapeutics Inc.
• 31.7. Celltrion Inc.
• 31.8. F. Hoffmann-La Roche AG
• 31.9. Immunomedics Inc.
• 31.10. MacroGenics Inc.
• 31.11. Pfizer Inc.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Teva Pharmaceutical Industries Ltd.
• 31.14. Puma Biotechnology Inc.
• 31.15. Seattle Genetics Inc.

32. Global Breast Cancer Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Monoclonal Antibodies Market

34. Recent Developments In The Breast Cancer Monoclonal Antibodies Market

35. Breast Cancer Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

• 35.1 Breast Cancer Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Breast Cancer Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Breast Cancer Monoclonal Antibodies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer